Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Fig. 4

MACE-free survival rates in the patients with diabetes mellitus and diabetic foot. The primary outcome was estimated using Cox regression models stratified according to trial and history of MACEs for the DPP4i-only group (a) or the insulin-only group (b) versus the combined therapy group. MACE major adverse cardiac event, DPP4i dipeptidyl peptidase-4 inhibitor

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us